In a bid to bolster its oncology pipeline, Takeda has entered into an exclusive license agreement with ImmunoGen. Through the deal, which is worth up to US$34 M, Takeda will gain Japan rights to Elahere® (mirvetuximab soravtansine-gynx) for the treatment of platinum-resistant ovarian cancer patients. Interestingly, the deal was announced three months after ImmunoGen disclosed its Phase III MIRASOL confirmatory trial results, evaluating the safety and efficacy of Elahere® in patients with folate receptor alpha-positive platinum-resistant ovarian cancer.